The therapeutic potential of targeting the APC/C, either by blocking the activation of the complex or the co-activators, has been examined in cancer using proTAME,15,26,27 withaferin A,43 NAHA (a hydroxamic acid derivative)44 and apcin.45 The small molecule proTAME is the only true/selective APC/C inhibitor known so far.26 ProTAME has already been described to cause a prolonged metaphase in cancer cells.15,26 Consistent with these observations, synchronised DLBCL and MCL cells released into proTAME treatment were found to accumulate in the G2/M phase. The gene discussed is APC; the disease is cancer.